文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

非酒精性脂肪性肝病中黏液层与肠道微生物群的相互作用:土壤与种子。

Interaction between mucus layer and gut microbiota in non-alcoholic fatty liver disease: Soil and seeds.

机构信息

Department of Translational Medicine Platform, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang 310015, China.

Department of School of Life Sciences, Zhejiang University of Traditional Chinese Medicine, Hangzhou, Zhejiang 310053, China.

出版信息

Chin Med J (Engl). 2023 Jun 20;136(12):1390-1400. doi: 10.1097/CM9.0000000000002711. Epub 2023 May 18.


DOI:10.1097/CM9.0000000000002711
PMID:37200041
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10278733/
Abstract

The intestinal mucus layer is a barrier that separates intestinal contents and epithelial cells, as well as acts as the "mucus layer-soil" for intestinal flora adhesion and colonization. Its structural and functional integrity is crucial to human health. Intestinal mucus is regulated by factors such as diet, living habits, hormones, neurotransmitters, cytokines, and intestinal flora. The mucus layer's thickness, viscosity, porosity, growth rate, and glycosylation status affect the structure of the gut flora colonized on it. The interaction between "mucus layer-soil" and "gut bacteria-seed" is an important factor leading to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Probiotics, prebiotics, fecal microbiota transplantation (FMT), and wash microbial transplantation are efficient methods for managing NAFLD, but their long-term efficacy is poor. FMT is focused on achieving the goal of treating diseases by enhancing the "gut bacteria-seed". However, a lack of effective repair and management of the "mucus layer-soil" may be a reason why "seeds" cannot be well colonized and grow in the host gut, as the thinning and destruction of the "mucus layer-soil" is an early symptom of NAFLD. This review summarizes the existing correlation between intestinal mucus and gut microbiota, as well as the pathogenesis of NAFLD, and proposes a new perspective that "mucus layer-soil" restoration combined with "gut bacteria-seed" FMT may be one of the most effective future strategies for enhancing the long-term efficacy of NAFLD treatment.

摘要

肠黏液层是分隔肠内容物和上皮细胞的屏障,也是肠道菌群黏附定植的“黏液层-土壤”。其结构和功能完整性对人体健康至关重要。肠黏液受饮食、生活习惯、激素、神经递质、细胞因子和肠道菌群等因素的调节。黏液层的厚度、黏度、孔隙率、增长率和糖基化状态影响着定植其上的肠道菌群结构。“黏液层-土壤”与“肠道细菌-种子”的相互作用是导致非酒精性脂肪性肝病(NAFLD)发病的重要因素。益生菌、益生元、粪便微生物移植(FMT)和灌洗微生物移植是治疗 NAFLD 的有效方法,但长期疗效不佳。FMT 专注于通过增强“肠道细菌-种子”来实现治疗疾病的目标。然而,缺乏对“黏液层-土壤”的有效修复和管理可能是“种子”不能在宿主肠道中良好定植和生长的原因,因为“黏液层-土壤”的变薄和破坏是非酒精性脂肪性肝病的早期症状。本综述总结了肠道黏液与肠道菌群之间的现有相关性,以及非酒精性脂肪性肝病的发病机制,并提出了一个新的观点,即“黏液层-土壤”的修复与“肠道细菌-种子”的 FMT 相结合可能是增强非酒精性脂肪性肝病治疗长期疗效的最有效策略之一。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05a8/10278733/7116f0b74240/cm9-136-1390-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05a8/10278733/4582ea06142d/cm9-136-1390-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05a8/10278733/7116f0b74240/cm9-136-1390-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05a8/10278733/4582ea06142d/cm9-136-1390-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05a8/10278733/7116f0b74240/cm9-136-1390-g002.jpg

相似文献

[1]
Interaction between mucus layer and gut microbiota in non-alcoholic fatty liver disease: Soil and seeds.

Chin Med J (Engl). 2023-6-20

[2]
Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.

Aliment Pharmacol Ther. 2019-8-2

[3]
Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.

J Gastroenterol. 2020-2

[4]
Gut microbiome and non-alcoholic fatty liver disease.

Prog Mol Biol Transl Sci. 2022

[5]
Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies.

Eur J Clin Microbiol Infect Dis. 2019-12-11

[6]
Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.

Expert Rev Gastroenterol Hepatol. 2019-1-25

[7]
Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies.

Rev Endocr Metab Disord. 2023-12

[8]
Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies.

Gut Microbes. 2023

[9]
Fighting Fatty Liver Diseases with Nutritional Interventions, Probiotics, Symbiotics, and Fecal Microbiota Transplantation (FMT).

Adv Exp Med Biol. 2019

[10]
Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view.

World J Gastroenterol. 2020-4-28

引用本文的文献

[1]
Gut microbiota in non-alcoholic fatty liver disease: Pathophysiology, diagnosis, and therapeutics.

World J Hepatol. 2025-6-27

[2]
Advances in the acting mechanism and treatment of gut microbiota in metabolic dysfunction-associated steatotic liver disease.

Gut Microbes. 2025-12

[3]
Cultivating complexity: Advancements in establishing in vitro models for the mucus-adhering gut microbiota.

Microb Biotechnol. 2024-10

[4]
Lactobacillus helveticus attenuates alcoholic liver injury via regulation of gut microecology in mice.

Microb Biotechnol. 2024-10

[5]
and NAFLD: pathophysiology and therapy.

Front Microbiol. 2024-3-20

[6]
Genetically Predicted Causal Effects of Gut Microbiota and Gut Metabolites on Digestive Tract Cancer: A Two-Sample Mendelian Randomization Analysis.

World J Oncol. 2023-12

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索